Detalhe da pesquisa
1.
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.
J Am Soc Nephrol
; 28(9): 2756-2767, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28400446
2.
C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot study.
Clin Kidney J
; 15(5): 922-928, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35498891
3.
Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
ACR Open Rheumatol
; 2(11): 662-671, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-33128347
4.
The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.
Lancet Diabetes Endocrinol
; 3(9): 687-96, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26268910